FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity
연구 도서관으로 돌아가기

New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

New Study Explores Combination Peptide Therapy for Crohn’s Disease and Obesity

Researchers at Eli Lilly are launching a Phase 3 clinical trial to investigate the effectiveness of mirikizumab in conjunction with tirzepatide for patients suffering from moderately to severely active Crohn's disease (CD) along with obesity or overweight conditions. This study aims to provide critical insights into how these peptide therapies can be used together to improve patient outcomes.

Background

Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract, and it often coexists with other health issues like obesity. Traditional treatments for CD include immunosuppressants and biologics, but many patients require additional support due to persistent symptoms or side effects. Peptide-based therapies have gained traction in recent years due to their targeted approach and lower risk profile compared to conventional medications.

Mirikizumab is a humanized monoclonal antibody that inhibits interleukin-23 (IL-23), which plays a significant role in immune response regulation. It has shown promise in treating moderate-to-severe plaque psoriasis and ulcerative colitis, making it an interesting candidate for CD treatment as well.

Tirzepatide, on the other hand, is a glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It’s primarily used to manage type 2 diabetes and obesity by regulating appetite and metabolic processes.

The combination of these two peptides in the context of Crohn's disease and obesity represents a novel approach to managing complex comorbidities, potentially offering relief from both gastrointestinal inflammation and weight-related health issues simultaneously.

Key Details

This Phase 3 clinical trial will recruit adult participants who are suffering from moderately to severely active CD along with obesity or overweight conditions. The study’s primary objective is to assess the efficacy and safety of mirikizumab when used either alone or in combination with tirzepatide over a period of up to 61 weeks.

Participants will be randomly assigned to receive one of several treatment regimens, including different dosages and administration schedules for both peptides. Researchers will monitor various metrics such as disease activity scores, quality-of-life measures, and adverse event rates to gauge the overall impact of the treatments on patient health.

The study's findings could pave the way for new therapeutic options that address multiple aspects of Crohn’s disease management, particularly in patients who struggle with obesity or being overweight. By combining these two peptides, researchers hope to unlock synergistic benefits that neither treatment can achieve independently.

Key Takeaways

  • Novel Combination Therapy: The study will explore the potential of using mirikizumab and tirzepatide together for managing Crohn’s disease in conjunction with obesity or being overweight.
  • Targeted Approach: Peptide-based therapies like mirikizumab offer a more precise targeting mechanism compared to traditional broad-spectrum medications, potentially reducing side effects.
  • Long-Term Safety Evaluation: The study will assess the safety profile of these treatments over an extended period of up to 61 weeks, providing crucial data on long-term use and patient outcomes.
  • Impact on Quality of Life: By addressing multiple health concerns simultaneously, this combined approach could significantly improve patients' quality of life.

What This Means

This clinical trial represents a significant step forward in the development of peptide-based therapies for complex medical conditions like Crohn’s disease and obesity. If successful, it could lead to new treatment guidelines that incorporate these peptides into standard care protocols, benefiting millions of people around the world who struggle with chronic inflammatory diseases and weight management issues.

As research continues to uncover the benefits and limitations of various peptide treatments, studies like this one are vital for advancing our understanding and improving patient outcomes. The broader peptide community will closely follow the results of this trial as they provide valuable insights into the future direction of peptide therapy development and application.

---

Source: ClinicalTrials.gov — Published 2026-05-20

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.